Results 171 to 180 of about 18,748 (206)

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

BJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics, Dániel Bacsó, Nadeen Samaien, Isabel Pinto Amorim das Virgens, Mahmoud Obeidat, Gergely Bánfi, Boris Hadaschik, Péter Hegyi, Péter Nyirády, Tibor Szarvas   +9 more
wiley   +1 more source

Identification of a Novel Trifluoromethyl-Bearing Flavonoid as a Promising Androgen Receptor Antagonist: Structure-Based Virtual Screening and In Vitro Study. [PDF]

Comput Struct Biotechnol J
Tadasee P, Khotavivattana T, Chaithirayanon K, Assawakosri S, Nutho B.   +4 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists for Liver Fibrosis: Potential Mechanisms and Research Progress. [PDF]

J Clin Transl Hepatol
Zheng H, Feng Y.
europepmc   +1 more source

TRPM3 regulates fear memory encoding and seizure susceptibility in the lateral amygdala

British Journal of Pharmacology, EarlyView.
Abstract Background and purpose TRPM3 is best known for its role as a peripheral sensor of pain and heat. Recent studies reporting gain‐of‐function TRPM3 mutations in patients with neurodevelopmental and epilepsy‐associated disorders suggest a previously unrecognized role of this channel in the brain.
Attila Gyéresi, Laura Mundrucz, Máté Deák, Angéla Kecskés, Éva Borbély, Viktória Kormos, Balázs Gaszner, Orsolya Mihály, Balázs István Tóth, Joris Vriens, Thomas Voets, Erzsébet Kövesdi, Miklós Kecskés   +12 more
wiley   +1 more source

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

Cancer Science, EarlyView.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei, Yasutaka Yamada, Takaaki Tamura, Masahiro Sugiura, Xue Zhao, Meng Ni, Adilan Aierken, Tomokazu Sazuka, Yusuke Imamura, Shinichi Sakamoto   +9 more
wiley   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

Cancer Science, EarlyView.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota, Tokiyoshi Tanegashima, Takahiko Hajime, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto   +8 more
wiley   +1 more source

GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome. [PDF]

EBioMedicine
Cotellessa L, Maitre H, Giton F, Bongiovanni S, Pigny P, Robin G, Catteau-Jonard S, Giacobini P.   +7 more
europepmc   +1 more source

Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

Cancer Science, EarlyView.
The glucocorticoid receptor NR3C1 drives prostate cancer radioresistance by upregulating ACSL4. High ACSL4 levels create a lipid metabolic vulnerability. The clinical agent DHA synergizes with ACSL4 to induce lipid peroxidation and ferroptosis, effectively overcoming radioresistance.
Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang   +7 more
wiley   +1 more source

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom. [PDF]

Br J Clin Pharmacol
Dhillon S, Antolin AA, Jones AM.
europepmc   +1 more source